Analysis of oral hypoglycemic drugs that are subject to reimbursement in Ukraine

Abstract

Increasing the affordability of pharmaceutical provision to the population is the most important task of the governments, especially in the context of health care reform. Therefore, considering that reimbursement of the cost of drugs increases their affordability, it is relevant to analyze the updated list of GLDs that are subject to reimbursement. The purpose of the work is to conduct an audit of oral GLDs for the treatment of type 2 diabetes, which are subject to reimbursement under the state program in Ukraine, and to study their affordability. The objects of the research were the State Register of Medicinal Products, the Register of Maximum Wholesale and Retail Prices for Drugs, which are subject to reimbursement under the program of state guarantees of medical care for the population. Bibliosemantic, marketing, analytical, graphical, generalizing analyzes and mathematical calculations were used. An audit was conducted of GLDs, except of insulin, for the treatment of patients with type 2 diabetes, the cost of which is subject to reimbursement under the program under the state guarantee program. Only three drugs under the INN are subject to reimbursement: metformin, glibenclamide, and gliclazide. The number of TNs is 51 Ukrainian-made and foreign-made GLDs, and the majority (76.9%) are domestic products. Metformin, gliclazide, and glibenclamide tablets are available in a sufficient assortment of 40 TN, 8 TN, and 3 TN tablets, respectively, in different dosages and packaging (No 30, No 60, No 90, No 120). There are no prolonged forms of metformin, although they are available on the pharmaceutical market of Ukraine. 3 glibenclamide drugs, 1 drug out of 8 – gliclazide, and 13 out of 40 drugs – metformin are subject to full reimbursement. Others require co-payments from the patient. Calculations of co-payments DDD of GLDs that are partially reimbursable, taking into account dosage and packaging, have been carried out. The co-payments for DDD ranges from UAH 0.111 to UAH 2.510 for gliclazide, and from UAH 0.105 to UAH 1.576 for metformin. The co-payments for foreign-made drugs is more than that of the domestic one. To increase the affordability of GLDs and the introduction of modern treatment schemes, it is necessary to expand the list of reimbursable GLDs, including prolonged forms of metformin and innovative drugs. Innovative drugs such as GLP1 and SGLT2 are recommended to be used at the beginning of treatment to prevent the development of DM complications.

Keywords

• hypoglycemic drugs
• diabetes mellitus
• assortment
• affordability
• reimbursement
• patient co-payments